Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Diagnosis & Disease Information
ASH 2022: New Findings in CLL
Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.
Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Risk of VTE 6-Fold Higher in CLL/MBL Than in General Population
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Immune Responses to SARS-CoV-2 mRNA Vaccines Vary in Patients With Hematologic Malignancies
Researchers evaluated the anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies in a real-world setting.
Zanubrutinib Appears Superior to Ibrutinib in Patients With Relapsed/Refractory CLL/SLL
Researchers sought to compare zanubrutinib with ibrutinib in patients with CLL/SLL.
Triplet Falls Short in Relapsed/Refractory Chronic Lymphocytic Leukemia
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
- Loading...
Loading...
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...